Manufacturers seeking CDMOs that can quickly develop complex formulations offering both body and mind benefits SIRIO Europe (Ayanda) – the European nutraceutical and pharmaceutical contract development and manufacturing organisation (CDMO) and member of SIRIO Group – forecasts a winter surge in requests from nutra brands for new ‘dual benefit’ mood enhancing formulations as a result of COVID-19 measures. The company said the normal winter increase in demand for mood enhancing formulations is being significantly accelerated by the ongoing effects of European and North American lockdowns and national restrictions. But rather than purchase these as stand-alone products, consumers are looking for nutraceuticals that also provide
The post COVID-19 winter lockdowns & national restrictions drive demand for ‘body and mind’ formulations say SIRIO Europe appeared first on Pharma Mirror Magazine.
